MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
secondary public offering
$46,582K
Proceeds from exercise of
warrants
$1,496K
Net cash provided by
financing activities
$46,468K
Canceled cashflow
$1,610K
Net increase in cash
and cash...
$3,056K
Canceled cashflow
$43,412K
Commissions paid on
secondary public offering
$1,398K
Payments on financed
insurance policies
$212K
Stock-based compensation
expense
$2,641K
Amortization of operating
lease right of use...
$538K
Depreciation expense
$34K
Net cash used in
operating activities
-$31,317K
Net cash used in
investing activities
-$12,095K
Canceled cashflow
$3,213K
Net loss
-$26,555K
Prepaid expense and
other current assets
$2,884K
Accounts payable and
accrued liabilities
-$2,505K
Purchases of marketable
securities
$12,071K
Purchases of property and
equipment
$24K
Change in fair value of
warrant liability
-$2,021K
Operating lease liability
-$565K
Back
Back
Cash Flow
source: myfinsight.com
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)